Resolvin E2 (RvE2) is a specialized pro-resolving mediator (SPM) of the E-series resolvin subfamily, biosynthesized from eicosapentaenoic acid (EPA) via sequential lipoxygenase-mediated oxygenations. RvE2 actively orchestrates inflammation resolution by blocking neutrophil infiltration, promoting macrophage-mediated efferocytosis, and restoring tissue homeostasis without immunosuppression. It functions as part of the coordinated SPM resolution program alongside RvE1 and RvE3.
Think of inflammation like a forest fire: the initial blaze (acute inflammation) is necessary to clear dead wood, but it must be actively extinguished before the entire forest burns. RvE2 is like a specialized firefighting foam—not just water that dilutes the flames, but a targeted chemical that actively suffocates the fire AND triggers the cleanup crew.
When neutrophils (the initial fire brigade) have done their job clearing debris and pathogens, RvE2 tells them "stop sending more trucks"—it blocks the recruitment signals that would bring additional neutrophils to the scene. Simultaneously, it activates macrophages (the cleanup crew) to clear away dead neutrophils and cellular debris without reigniting inflammation. The foam doesn't just stop the fire; it transforms the charred landscape back into fertile soil, ready for regrowth. But here's the catch: you can only make this foam if you have the right raw material (EPA) and functional foam-mixing equipment (lipoxygenase enzymes). No EPA substrate or damaged enzymes from oxidative stress? The fire smolders on, never truly resolved—chronic inflammation.
RvE2 biosynthesis follows a stereospecific enzymatic cascade requiring adequate EPA substrate and functional lipoxygenase pathways:
Biosynthetic Pathway:
- EPA → 18-HEPE (via 5-LOX or acetylated COX-2) → 18-hydroperoxy-EPE intermediate
- 18-hydroperoxy-EPE → RvE2 (via subsequent enzymatic reduction and isomerization)
- Alternative pathway: 15-LOX can initiate EPA oxygenation at C-18 position
- Final structure: 5S,18(R/S)-dihydroxy-EPE (exact stereochemistry determines biological potency)
graph TD
A[EPA from diet/membranes] --> B[5-LOX or acetylated COX-2]
B --> C[18-HEPE intermediate]
C --> D[Enzymatic reduction]
D --> E["RvE2: 5S,18-dihydroxy-EPE"]
E --> F[Receptor binding]
F --> G[BLT1 antagonism]
F --> H[ChemR23/ERV1 partial agonism]
G --> I[Blocks neutrophil recruitment]
H --> J[Enhances macrophage efferocytosis]
I --> K[Resolution of inflammation]
J --> K
L[Oxidative stress] -.inhibits.-> B
M[EPA deficiency] -.blocks.-> A
Receptor Mechanisms:
- BLT1 (leukotriene B4 receptor): RvE2 acts as competitive antagonist, blocking LTB4-mediated neutrophil chemotaxis and activation
- ChemR23/ERV1: Partial agonist activity (weaker than RvE1), promotes Efferocytosis via Akt pathway activation in macrophages
- Intracellular signaling: RvE2 → receptor binding → decreased NF-kB nuclear translocation → reduced pro-inflammatory cytokine transcription (IL-1β, TNF-α, IL-6)
- Neutrophil effects: Reduced L-selectin shedding, decreased CD86 expression, inhibited NET formation (NETosis)
Macrophage Polarization:
RvE2 → M2-like phenotype shift → increased IL-10 production + enhanced phagocytic capacity → clearance of apoptotic cells without secondary necrosis → prevention of chronic inflammation
Metabolic Inactivation:
- Eicosanoid oxidoreductases convert RvE2 to less active metabolites
- Dehydrogenation and β-oxidation pathways clear RvE2 from tissues
- Half-life: approximately 3-8 minutes in vivo (rapid clearance ensures temporal resolution control)
Patient Populations:
RvE2 deficiency or impaired synthesis is clinically relevant in:
Metamodel Integration:
- Lipid mediator class switching: RvE2 represents the metabolic pivot from pro-inflammatory eicosanoids (PGE2, LTB4) to pro-resolving mediators—the biological "off switch" that modern lifestyles often fail to activate
- Selfish Immune System: In evolutionary mismatch scenarios (chronic stress, high omega-6:omega-3 ratios >15:1), the immune system becomes "selfishly" pro-inflammatory, depleting resolution capacity and shifting resources toward ongoing threat responses
- Evolutionary mismatch: Hunter-gatherer omega-6:omega-3 ratios (~1-2:1) supported robust SPM synthesis; Western diets (15-20:1) create EPA substrate scarcity, impairing RvE2 production
Intervention Strategies:
- Substrate optimization: EPA supplementation 1-2g daily (marine sources preferred over plant-based ALA conversion, which is <5% efficient)
- Enzyme protection: Reduce Oxidative Stress via antioxidant-rich foods, polyphenols (Curcumin, Resveratrol), and mitochondrial support (CoQ10)
- Aspirin timing: Low-dose Aspirin (75-100mg) acetylates COX-2, creating Aspirin-triggered resolvins including AT-RvE intermediates
- Lifestyle triggers: Cold exposure, Exercise, and Intermittent fasting upregulate lipoxygenase expression and SPM biosynthetic capacity
- Avoid resolution blockers: NSAIDs (except aspirin), chronic Alcohol, trans fats, and excessive refined carbohydrates impair RvE2 synthesis
Biomarker Considerations:
- Plasma RvE2 levels: typically 10-100 pg/mL in healthy individuals (specialized lipidomics required)
- Omega-3 index (target >8%) correlates with SPM biosynthetic capacity
- Resolution interval (R_i)]: measure of how quickly inflammation resolves; RvE2 shortens R_i in experimental models
- Elevated CRP + low omega-3 index = high probability of impaired resolution
- RvE2 structure: 5S,18(R/S)-dihydroxy-eicosapentaenoic acid, molecular weight 334.5 Da
- Biosynthesis requires minimum EPA membrane incorporation of ~4-5% of total fatty acids for adequate substrate
- Acts as BLT1 antagonist (ICâ‚…â‚€ ~10-50 nM depending on assay), blocking LTB4 pro-inflammatory signaling
- Reduces neutrophil infiltration by 40-60% in experimental peritonitis models at nanomolar concentrations
- Enhances macrophage efferocytosis 2-3 fold compared to unstimulated conditions
- Synergizes with RvE1 and RvE3—combined E-series resolvins show additive resolution effects
- Plasma half-life: 3-8 minutes; rapid metabolic inactivation ensures tight temporal control
- Oxidative Stress (elevated ROS) reduces 5-LOX and 15-LOX activity by 30-50%, impairing RvE2 synthesis
- Western omega-6:omega-3 ratios (15-20:1) create competitive substrate inhibition—arachidonic acid metabolites dominate over EPA-derived SPMs
- Heat-stable: remains bioactive after moderate cooking (unlike some DHA-derived protectins)
- Specialized pro-resolving mediators (SPMs) — RvE2 is a key member of the SPM superfamily driving active inflammation resolution
- Resolvins — parent category; E-series resolvins (EPA-derived) vs D-series (DHA-derived)
- RvE1 — closely related E-series resolvin; works synergistically via overlapping and distinct receptor pathways
- RvE3 — third member of E-series resolvin family; combined administration enhances resolution kinetics
- EPA — obligate omega-3 precursor; dietary intake directly determines RvE2 biosynthetic capacity
- Omega-3 — broader class of essential fatty acids supporting resolution; DHA produces D-series resolvins
- Lipid mediator class switching — RvE2 synthesis represents the metabolic transition from pro-inflammatory to pro-resolving lipid mediators
- 5-LOX — key biosynthetic enzyme catalyzing initial EPA oxygenation to 18-HEPE
- 15-LOX — alternative enzymatic pathway for RvE2 biosynthesis depending on tissue context
- COX-2 — when acetylated by aspirin, generates aspirin-triggered resolvin precursors
- Efferocytosis — RvE2 actively promotes macrophage clearance of apoptotic neutrophils, preventing secondary necrosis
- NF-kB — RvE2 suppresses nuclear translocation, reducing pro-inflammatory gene transcription
- Neutrophil — RvE2 blocks recruitment and activation, limiting tissue infiltration during resolution
- Macrophage Polarization — RvE2 shifts macrophages toward M2-like phenotype with enhanced phagocytic and repair functions
- LTB4 — pro-inflammatory leukotriene; RvE2 antagonizes its receptor (BLT1) to block neutrophil chemotaxis
- IL-10 — anti-inflammatory cytokine; RvE2 stimulates IL-10 production by macrophages
- Oxidative Stress — major inhibitor of RvE2 biosynthetic enzymes; antioxidant support preserves resolution capacity
- Inflammation — RvE2 actively terminates inflammatory responses without immunosuppression
- Resolution interval (R_i) — RvE2 shortens the time required for complete inflammation resolution
- ChemR23/ERV1 — receptor for E-series resolvins; mediates efferocytosis and anti-inflammatory signaling
- Chronic inflammation — RvE2 deficiency contributes to failed resolution and persistent low-grade inflammation
- Type 2 Diabetes — impaired RvE2 synthesis linked to unresolved adipose tissue inflammation and insulin resistance
- Atherosclerosis — RvE2 promotes plaque stability by resolving vascular inflammation and enhancing macrophage efferocytosis
- ARDS — RvE2 shows therapeutic potential in resolving acute lung injury and preventing fibrosis
- Periodontitis — local RvE2 administration reduces gingival inflammation and promotes healing
- Module 5: Core SPM biochemistry, resolution pharmacology, and lipid mediator class switching mechanisms